Inventor · disambiguated record
Olivier Hermine
Also filed as: HERMINE OLIVIER
16 granted patents·19 pending applications·17 citations·filing 2002–2022
88Inventor score
Files withINST NAT SANTE RECH MED17CELGENE CORP3AB SCIENCE2CENTRE HOSPITALIER NAT DOPHTALMOLOGIE QUINZE VINGTS1CENTRE NAT RECH SCIENT1
Top patents by PatentIndex Score
35 records- 0176US9463217B1Methods and pharmaceutical compositions for treatment of retinal occlusionINST NAT SANTE RECH MED·Filed 2013·Granted Oct 11, 2016·4 cites·2 claims
- 0266US8784797B2Methods, pharmaceutical compositions and kits for use in the treatment of adult T-cell leukemia/lymphomaDE THE HUGUES·Filed 2009·Granted Jul 22, 2014·0 cites·6 claims
- 0365US7976841B2Anti TfR antibodyINST NAT SANTE RECH MED·Filed 2004·Granted Jul 12, 2011·8 cites·11 claims
- 0464US9107893B2Methods, pharmaceutical compositions and kits for use in the treatment of adult T-cell leukemia/lymphomaINST NAT SANTE RECH MED·Filed 2014·Granted Aug 18, 2015·0 cites·4 claims
- 0564US7727731B2Potent, selective and non toxic c-kit inhibitorsAB SCIENCE·Filed 2002·Granted Jun 1, 2010·2 cites·24 claims
- 0661US10151745B2Methods for determining the risk of acute graft versus host diseaseINST NAT SANTE RECH MED·Filed 2013·Granted Dec 11, 2018·2 cites·12 claims
- 0761US9377471B2Methods and compositions for the treatment of β-thalassemiaINST NAT SANTE RECH MED·Filed 2014·Granted Jun 28, 2016·1 cites·2 claims
- 0854US2025332150A1Methods for treating notch1-driven cancersINST NAT SANTE RECH MED·Filed 2021·Application pending·0 cites
- 0953US11065230B2Methods and pharmaceutical compositions for the treatment of systemic mastocytosisINST NAT SANTE RECH MED·Filed 2017·Granted Jul 20, 2021·0 cites·4 claims
- 1051US2021308106A1Methods and pharmaceutical compositions for the treatment of systemic mastocytosisINST NAT SANTE RECH MED·Filed 2021·Application pending·0 cites
- 1151US2024374564A1Novel serotonin derivatives and their uses for treating iron-associated disordersCENTRE NAT RECH SCIENT·Filed 2022·Application pending·0 cites
- 1250US2022348660A1Methods for the treatment of adult t-cell leukemia/lymphomaINST NAT SANTE RECH MED·Filed 2020·Application pending·0 cites
- 1350US2019049469A1Biomarker for use in treating anemiaCELGENE CORP·Filed 2018·Application pending·0 cites
- 1449US2025011792A1Irap inhibitors for use in the treatment of inflammatory diseasesINST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 1548US11629192B2Methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathwayINST NAT SANTE RECH MED·Filed 2018·Granted Apr 18, 2023·0 cites·4 claims
- 1648US2015276766A1Biomarker for use in treating anemiaCELGENE CORP·Filed 2013·Application pending·0 cites
- 1748US2012135002A1Compounds and Methods for the Treatment of CancerCRUZ MOURA IVAN·Filed 2009·Application pending·0 cites
- 1845US12472164B2Masitinib for the treatment of sickle cell diseaseAB SCIENCE·Filed 2020·Granted Nov 18, 2025·0 cites·17 claims
- 1945US10647752B2Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1INST NAT SANTE RECH MED·Filed 2016·Granted May 12, 2020·0 cites·6 claims
- 2045US2024002519A1Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell diseaseINST NAT SANTE RECH MED·Filed 2021·Application pending·0 cites
- 2145US2022073626A1Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancerINSTITUT NAT DE LA SANTE ET DE LA RECHECHE MEDICALE INSERM·Filed 2020·Application pending·0 cites
- 2244US9861615B2Methods and pharmaceutical compositions for the treatment of beta-thalassemiasINSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE)·Filed 2014·Granted Jan 9, 2018·0 cites·6 claims
- 2344US2016368975A1Methods and compositions for the treatment of beta-thalassemiaINST NAT DE LA SANTE ET DE LA RECH MEDICALE (INSERM)·Filed 2016·Application pending·0 cites
- 2443US9675590B2Methods and pharmaceutical compositions for the treatment of myelodysplastic syndromesINSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE)·Filed 2015·Granted Jun 13, 2017·0 cites·2 claims
- 2542US2022307021A1A neuropilin antagonist in combination with a p38alpha-kinase inhibitor for the treatment of cancerINST NAT SANTE RECH MED·Filed 2020·Application pending·0 cites
- 2639US10617658B2Use of hydroxycarbamide for preventing retinal nonperfusionCENTRE HOSPITALIER NAT DOPHTALMOLOGIE QUINZE VINGTS·Filed 2016·Granted Apr 14, 2020·0 cites·11 claims
- 2739US2015268219A1Method for Renal TransplantationUNIV PARIS DIDEROT PARIS 7·Filed 2014·Application pending·0 cites
- 2838US11389434B2Methods and pharmaceutical compositions for the treatment of mast cell diseasesINST NAT SANTE RECH MED·Filed 2018·Granted Jul 19, 2022·0 cites·7 claims
- 2937US2015266950A1Methods for treating anemiaCELGENE CORP·Filed 2013·Application pending·0 cites
- 3035US2022008514A1Combined use of selective serotonin reuptake inhibitors and hematopoietic growth factors for treating hematopoietic diseasesIMAGINE INST DES MALADIES GENETIQUES NECKER ENFANTS MALADES·Filed 2019·Application pending·0 cites
- 3131US2017051062A1Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling PathwayINSERM (INSTITUT NAT DE LA SANTE ET DE LA RECH MEDICALE)·Filed 2015·Application pending·0 cites
- 3230US2013190251A1Method for predicting the responsiveness to chemotherapyWITKO-SARSAT VERONIQUE·Filed 2011·Application pending·0 cites
- 3328US2015197574A1Use of transferrin receptor antagonist for the treatment of thalassemiaINST NAT SANTE RECH MED·Filed 2013·Application pending·0 cites
- 3422US2018031579A1Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such diseaseINSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECH MÉDICALE)·Filed 2016·Application pending·0 cites
- 3521US10111896B2Composition comprising a combination of DNA methylation inhibitor and a vitamin D receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapseINST NAT SANTE RECH MED·Filed 2015·Granted Oct 30, 2018·0 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when Olivier Hermine files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →